Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis.

Liang D, Liu Q, Liu M, Li Y

Open source

DOI
10.3389/fimmu.2026.1910678
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1910678,
  title = {Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis.},
  author = {Liang D and Liu Q and Liu M and Li Y},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1910678},
  url = {https://doi.org/10.3389/fimmu.2026.1910678}
}

RIS

TY  - JOUR
TI  - Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis.
AU  - Liang D
AU  - Liu Q
AU  - Liu M
AU  - Li Y
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1910678
UR  - https://doi.org/10.3389/fimmu.2026.1910678
ER  - 

APA

D, L., Q, L., M, L., & Y, L. (2026). Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1910678

Source records